Figure 4 Progression-free survival, according to treatment group

Slides:



Advertisements
Similar presentations
Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Advertisements

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.
Treatment of early-stage Hodgkin lymphoma
Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.
Figure 3 Life expectancy at birth in all countries included
Figure 1 Histopathology of low-grade glioma
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 5 Schematic illustration of different clinical trial designs
Figure 3 Molecular subgroups of glioblastoma,
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Proportion of patients for whom NEDA
Figure 5 Number of AHSCT procedures for
Nat. Rev. Endocrinol. doi: /nrendo
Figure 1 Diagnostic tiers of Parkinson disease as single disease
Figure 2 Precision medicine based on a network approach
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Principles of therapeutic ultrasound
Figure 4 Flow chart of the MDS MSA Study Group aims
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Ali F. AbuRahma, MD  Journal of Vascular Surgery 
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Jamal H. Carter, Samantha N. McNulty, Patrick J. Cimino, Catherine E
Figure 6 Combining population-wide and high-risk strategies
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Nat. Rev. Neurol. doi: /nrneurol
Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise  Chad G. Rusthoven, MD, Brian.
Figure 2 Logistical requirements for autologous
Nat. Rev. Neurol. doi: /nrneurol
Detection rate for EGFR mutations in cfDNA.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
PRISMA study flow diagram
George Blumenschein, MD, John V. Heymach, MD, PhD 
Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.
Figure 3 Overall survival, according to treatment group
Figure 1 Timing of the effects of deep brain stimulation
Osteoarthritis year 2010 in review: non-pharmacologic therapy
Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.
Figure 3 Rett syndrome severity and age at diagnosis by mutation type
Nat. Rev. Neurol. doi: /nrneurol
PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Craniospinal irradiation proton therapy for medulloblastoma
Cost Effectiveness of Intraoperative MRI for Treatment of High-Grade Gliomas Compared with neuronavigation systems, intraoperative MRI reliably maximizes.
Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.
Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas  Kripa Guram, BS, Mark Smith,
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).
(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.
The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.
(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of
Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders  Martin Benesch, MD, H. Joachim.
Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.
(A) Survival curves according to clinical response.
Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.
Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.
Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.
Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.
Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.
Presentation transcript:

Figure 4 Progression-free survival, according to treatment group Figure 4 | Progression-free survival, according to treatment group. Results from the Radiation Therapy Oncology Group (RTOG) 9802 trial7. a | Progression-free survival of all patients by treatment. b | Progression-free survival of patients with IDH1-Arg132His mutations by treatment group. Insufficient material was available for infrequent IDH mutations or 1p/19q codeletion. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Buckner, J. et al. (2017) Management of diffuse low-grade gliomas in adults — use of molecular diagnostics Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.54